Drugs / HS-10375
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05435248 | Mar 2022 → Mar 2025 overdue | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435248 ↗ |
| Action | Inhibit | “HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S.” NCT05435248 ↗ |
| Modality | Small molecule | “HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S.” NCT05435248 ↗ |
| Route | Oral | “HS-10375 will be administered orally once daily in a continuous regimen” NCT05435248 ↗ |
| Target | EGFR | “HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S.” NCT05435248 ↗ |